Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI)

MLA

Schoeffski, P., et al. Randomized, Open-Label, Multicenter, Phase 3 Study of Eribulin versus Dacarbazine in Patients (Pts) with Leiomyosarcoma (LMS) and Adipocytic Sarcoma (ADI). EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..13f6062f5809454c4b654f071408f9f9&authtype=sso&custid=ns315887. Accessed 11 Nov. 2024.

APA

Schoeffski, P., Robert G. Maki, Italiano, A., Gelderblom, H., Choy, E., Grignani, G., Camargo, V., Bauer, S., Rha, S. Y., Chawla, S., Blay, J.-Y., Hohenberger, P., D Adamo, D., Chen, R., Chmielowski, B., Le Cesne, A., George, D., & Patel, S. (n.d.). Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).

Chicago

Schoeffski, P., Robert G. Maki, A. Italiano, H. Gelderblom, E. Choy, G. Grignani, V. Camargo, et al. 2024. “Randomized, Open-Label, Multicenter, Phase 3 Study of Eribulin versus Dacarbazine in Patients (Pts) with Leiomyosarcoma (LMS) and Adipocytic Sarcoma (ADI).” Accessed November 11. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..13f6062f5809454c4b654f071408f9f9&authtype=sso&custid=ns315887.